A new class of antibody-drug conjugates with potent dna alkylating activity

Molecular Cancer Therapeutics

Volumn 15, Issue 8, 2016, Pages 1870-1878

  Miller, Michael L ^a   Fishkin, Nathan E ^a   Li, Wei ^a   Whiteman, Kathleen R ^a   Kovtun, Yelena ^a   Reid, Emily E ^a   Archer, Katie E ^a   Maloney, Erin K ^a   Audette, Charlene A ^a   Mayo, Michele F ^a,b   Wilhelm, Alan ^a   Modafferi, Holly A ^a   Singh, Rajeeva ^a   Pinkas, Jan ^a   Goldmacher, Victor ^a   Lambert, John M ^a   Chari, Ravi V J ^a  

^a IMMUNOGEN INC   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKYLATING AGENT; ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; ANTIBODY DRUG CONJUGATE 1C; ANTIBODY DRUG CONJUGATE 3A; ANTIBODY DRUG CONJUGATE 3B; ANTIBODY DRUG CONJUGATE 3C; ANTIBODY DRUG CONJUGATE 4A; ANTIBODY DRUG CONJUGATE 5A; ANTIBODY DRUG CONJUGATE 5C; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BENZODIAZEPINE DERIVATIVE; CD33 ANTIGEN; CELL DNA; EPITHELIAL CELL ADHESION MOLECULE; FOLATE RECEPTOR 1; IMGN 779; INDOLE DERIVATIVE; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; SODIUM BOROHYDRIDE; UNCLASSIFIED DRUG; DNA; DNA ADDUCT;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CANCER THERAPY; CELL KILLING; COMET ASSAY; CYTOTOXICITY; DNA ADDUCT; DNA CROSS LINKING; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IC50; LIGAND BINDING; MIXED CELL CULTURE; MOUSE; MYELOID LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; THERAPEUTIC INDEX; THROMBOCYTE COUNT; TREATMENT OUTCOME; TUMOR REGRESSION; ANIMAL; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PRECLINICAL STUDY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BYSTANDER EFFECT; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DNA; DNA ADDUCTS; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNOCONJUGATES; MICE; MOLECULAR STRUCTURE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84986333489     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0184     Document Type: Article

References (35)

1. Frei E III. Combination cancer therapy: presidential address. Cancer Res 1972;32:2593-607.
2. Issell BF, Crooke ST. Maytansine. Cancer Treat Rev 1978;5:199-207.
3. Pitot HC, McElroy EA Jr, Reid JM, Windebank AJ, Sloan JA, Erlichman C, et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 1999;5:525-31.
4. Edelman MJ, Gandara DR, Hausner P, Israel V, Thornton D, DeSanto J, et al. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2003;39:197-9.
5. Cristofanilli M, Bryan WJ, Miller LL, Chang AY, Gradishar WJ, Kufe DW, et al. Phase II study of adozelesin in untreated metastatic breast cancer. Anticancer Drugs 1998;9:779-82.
6. Pitot HC, Reid JM, Sloan JA, Ames MM, Adjei AA, Rubin J, et al. A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin Cancer Res 2002;8:712-7.
7. Chari RV, Miller ML, Widdison WC. Antibody-drug conjugates: An emerging concept in cancer therapy. Angewandte Chemie 2014;53: 3796-827.
8. Chudasama V, Maruani A, Caddick S. Recent advances in the construction of antibody-drug conjugates. Nat Chem 2016;8:114-9.
9. Diamantis N, Banerji U. Antibody-drug conjugates-an emerging class of cancer treatment. Br J Cancer 2016;114:362-7.
10. Chari RVJ. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008;41:98-107.
11. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013;64:15-29.
12. Katz J, Janik JE, Younes A. Brentuximab Vedotin (SGN-35). Clin Cancer Res 2011;17:6428-36.
13. Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res 2014;20: 4436-41.
14. Lambert JM, Chari RV. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 2014;57:6949-64.
15. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013;121:4854-60.
16. Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 2015;7:302ra136.
17. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate utilizing a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013;122:1455-63.
18. Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem 2013;24:1256-63.
19. Hochhauser D, Meyer T, Spanswick VJ, Wu J, Clingen PH, Loadman P, et al. Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. Clin Cancer Res 2009;15: 2140-7.
20. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006;49:4392-408.
21. Zhao RY, Wilhelm SD, Audette C, Jones G, Leece BA, Lazar AC, et al. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem 2011;54:3606-23.
22. Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010;70:2528-37.
23. Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res 2004;64:6693-9.
24. Foley KP, Zhou D, Borella C, Wu Y, Zhang M, Jiang J, et al. The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors. J Pharmacol Exp Ther 2012;343:529-38.
25. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991;51:4845-52.
26. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90.
27. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21.
28. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibodydrug conjugate. Clin Cancer Res 2010;16:888-97.
29. Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, et al. IMGN853, a folate receptor-alpha (FRalpha)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRalpha-expressing tumors. Mol Cancer Ther 2015;14:1605-13.
30. Zhao RY, Erickson HK, Leece BA, Reid EE, Goldmacher VS, Lambert JM, et al. Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. J Med Chem 2012;55:766-82.
31. Owonikoko TK, Hussain A, Stadler WM, Smith DC, Kluger H, Molina AM, et al. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol 2016;77:155-62.
32. van der Lee MM, Groothuis PG, Ubink R, van der Vleuten MA, van Achterberg TA, Loosveld EM, et al. The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers. Mol Cancer Ther 2015;14:692-703.
33. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-44.
34. Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, et al. Disulfidelinked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 2011;22:717-27.
35. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17:114-24.